We are pleased to announce that FairJourney Biologics has been named as one of the 500 fastest-growing EMEA tech companies in the Deloitte Technology Fast 500 with FairJourney ranking 293 recognising the company’s 439 percent growth.
Full list can be found here: https://www2.deloitte.com/
The inclusion makes it the second time in a row FairJourney Biologics has been featured with growth of 865 percent in Deloitte’s 2018 Fast 500 awards.
About Deloitte Fast 500: The Deloitte Technology Fast 500™ EMEA program is an objective industry ranking that recognizes the fastest-growing technology companies in Europe, the Middle East, and Africa (EMEA) during the past four years. The program is supported by the Deloitte Technology Fast 50 initiatives, which rank high-growth technology companies by location or specifically defined geographic area.
About FairJourney Biologics: FairJourney Biologics is a leading biologics CRO, providing integrated services across antibody discovery, engineering and production to global biopharma. Founded in 2012 and headquartered in Porto, FairJourney has grown to over 90 highly technically skilled employees today.
The Company operates a flexible, customer-oriented ‘one-stop shop’ approach to biologics development focused on quality, reliability and partnership. FairJourney has successfully completed more than 460 projects for over 70 customers across big pharma and leading biotech companies to date. The Company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries.
In May 2020, FairJourney Biologics joined forces with IONTAS to create a global leader in outsourced antibody discovery services. Read more here: https://bit.ly/3gKQ0qG